The other risk in waiting for non-memantine results is missing a possible deal with a large biotech, either for a region (Japan?) or for a distinct indication (MS?).
If a deal contains significant upfront cash (> $50M) and large milestones, then cash is no longer a concern and several new trials can be started.
I could see the share price easily doubling with a partnership that brings in significant cash.
News 
Market Data 
Discover 
